<DOC>
	<DOCNO>NCT00317759</DOCNO>
	<brief_summary>RATIONALE : Biological therapy cellular adoptive immunotherapy use different way stimulate immune system stop cancer cell grow . Fludarabine may help immune system kill cancer cell . PURPOSE : Phase I trial study effectiveness fludarabine follow cellular adoptive immunotherapy treat patient metastatic melanoma .</brief_summary>
	<brief_title>Fludarabine Followed By Adoptive Immunotherapy Treating Patients With Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety toxicity adoptive immunotherapy comprise autologous CD8+ antigen-specific cytotoxic T-lymphocyte ( CTL ) clone fludarabine patient stage IV melanoma . - Determine duration vivo persistence CTL clone patient . Secondary - Determine antitumor effect regimen patient . OUTLINE : This open-label , nonrandomized study . Patients undergo leukapheresis weekly phlebotomy collection peripheral blood mononuclear cell autologous antigen-specific CD8+ cytotoxic T-lymphocyte ( CTL ) clone generate . Patients receive autologous antigen-specific CD8+ CTL clone IV 30-60 minute day 0 21 absence rapid disease progression unacceptable toxicity . Patients also receive fludarabine IV daily day 14-18 . Patients follow 1 year . PROJECTED ACCRUAL : A total 12 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma Stage IV disease HLAA2 A3expressing disease Bidimensionally measurable residual disease palpation radiographic imaging ( e.g. , xray CT scan ) No CNS metastases Previously treat CNS involvement allow provided evidence CNS disease least 2 month completion therapy PATIENT CHARACTERISTICS : Age 18 75 Performance status Karnofsky 80100 % Life expectancy More 6 month Hematopoietic Platelet count &gt; 100,000/mm^3 Absolute neutrophil count &gt; 2,000/mm^3 Hepatic SGOT great 3 time upper limit normal Bilirubin great 1.6 mg/dL INR great 1.5 time normal Renal Creatinine great 2.0 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular No congestive heart failure No clinically significant hypotension No symptom coronary artery disease No cardiac arrhythmia EKG require drug therapy Pulmonary No clinically significant pulmonary dysfunction FEV_1 least 1.0 L* DLCO least 45 % * NOTE : *For patient history pulmonary dysfunction Immunologic No active infection No oral temperature great 38.2Â°C within past 48 hour No systemic infection require chronic maintenance suppressive therapy Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy ( e.g. , interleukin , interferon , melanoma vaccine , IV immunoglobulins , expand polyclonal tumorinfiltrating lymphocyte , lymphokineactivated killer therapy ) Chemotherapy At least 3 week since prior chemotherapy ( standard experimental ) Endocrine therapy No concurrent steroid Radiotherapy At least 3 week since prior radiotherapy Surgery Not specify Other At least 3 week since prior immunosuppressive therapy No concurrent pentoxifylline No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>